Sebastian Seiguer
Principal investigator, leads EMOCHA MOBILE HEALTH, INC..
Digital healthFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$11.7MFederal grants as PI22 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
22 awards · $11.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 1, 2026 | NIH | SBIR Phase II ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) | $50K | EMOCHA MOBILE HEALTH, INC. |
| Sep 4, 2025 | NIH | SBIR Phase II ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) | $649K | EMOCHA MOBILE HEALTH, INC. |
| Jul 9, 2025 | NIH | SBIR Phase II Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program | $650K | EMOCHA MOBILE HEALTH, INC. |
| Aug 23, 2024 | NIH | SBIR Phase II ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) | $612K | EMOCHA MOBILE HEALTH, INC. |
| Jul 26, 2024 | NIH | SBIR Phase II Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program | $659K | EMOCHA MOBILE HEALTH, INC. |
| Mar 25, 2024 | NIH | SBIR Phase II Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients | $837K | EMOCHA MOBILE HEALTH, INC. |
| Sep 6, 2023 | NIH | SBIR Phase II ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) | $643K | EMOCHA MOBILE HEALTH, INC. |
| Aug 1, 2023 | NIH | SBIR Phase II Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program | $654K | EMOCHA MOBILE HEALTH, INC. |
| Mar 31, 2023 | NIH | SBIR Phase II Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients | $839K | EMOCHA MOBILE HEALTH, INC. |
| Aug 31, 2021 | NIH | SBIR Phase II Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients | $728K | EMOCHA MOBILE HEALTH, INC. |
| Sep 21, 2020 | NIH | STTR Phase I Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program | $225K | EMOCHA MOBILE HEALTH, INC. |
| Sep 4, 2020 | NIH | SBIR Phase II Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients | $745K | EMOCHA MOBILE HEALTH, INC. |
| Sep 20, 2019 | NIH | SBIR Phase II Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients | $222K | EMOCHA MOBILE HEALTH, INC. |
| Jul 31, 2019 | NIH | SBIR Phase II Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine | $356K | EMOCHA MOBILE HEALTH, INC. |
| Jul 19, 2019 | NIH | SBIR Phase II Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine | $624K | EMOCHA MOBILE HEALTH, INC. |
| Mar 11, 2019 | NIH | SBIR Phase II Evaluation of National Video Directly Observed Therapy Implementation | $496K | EMOCHA MOBILE HEALTH, INC. |
| Jan 16, 2019 | NIH | SBIR Phase II Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine | $828K | EMOCHA MOBILE HEALTH, INC. |
| Aug 5, 2018 | NIH | SBIR Phase II Evaluation of National Video Directly Observed Therapy Implementation | $500K | EMOCHA MOBILE HEALTH, INC. |
| Jul 11, 2018 | NIH | SBIR Phase II Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine | $732K | EMOCHA MOBILE HEALTH, INC. |
| May 22, 2017 | NIH | SBIR Phase II Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine | $225K | EMOCHA MOBILE HEALTH, INC. |
| Jul 6, 2016 | NIH | SBIR Phase I Development and Assessment of Video-Based Directly Observed Therapy for Tuberculosis | $194K | EMOCHA MOBILE HEALTH, INC. |
| Sep 25, 2015 | NIH | SBIR Phase I Development and Assessment of Video-Based Directly Observed Therapy for Tuberculosis | $199K | EMOCHA MOBILE HEALTH, INC. |
Peer ranks
Federal funding#6
Awards as PI#4
Patents#45
Companies
- EMOCHA MOBILE HEALTH, INC.Leads (SEC Form D) · Digital health
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.